Salarius Pharmaceuticals Inc Stock Price, News & Analysis

On March 10, 2022, Salarius Pharmaceuticals (SLRX) reported key corporate events and financial results for 2021. The company expanded its cancer therapy pipeline by acquiring SP-3164, a targeted protein degrader aimed at treating hematologic and solid tumors. Salarius reported a net loss of $12.8 million for the year, with cash reserves totaling $29.2 million, expected to support operations through 2023. Upcoming updates on clinical trials for both SP-3164 and seclidemstat are anticipated, with optimism for growth in 2022 and beyond.

Salarius Pharmaceuticals (Nasdaq: SLRX) will host a conference call and audio webcast on March 10, 2022, at 5:00 p.m. ET to discuss its financial results for the year ended December 31, 2021. The call will provide insights into its clinical developments, including seclidemstat, a cancer therapy in Phase 1/2 trials for Ewing sarcoma. The company has secured Fast Track, Orphan Drug, and Rare Pediatric Disease Designations from the FDA for this indication. Interested participants can join via provided U.S. and international phone numbers.

Salarius Pharmaceuticals (Nasdaq: SLRX) announced that CEO David Arthur will present at the Diamond Equity Research Emerging Growth Invitational 2022 Virtual Conference on February 24, 2022, at 10:20 a.m. ET. The presentation will focus on the company’s progress, including the Phase 1/2 clinical trial of seclidemstat, aimed at treating sarcomas and pediatric cancers, and recent acquisitions in protein degradation assets like SP-3164. Investors can register for free to attend the conference, with a recording available post-event on the company’s website.

Salarius Pharmaceuticals (Nasdaq: SLRX) announced that CEO David Arthur will present at the BIO CEO & Investor Conference, February 14-17, 2022, in New York. The presentation will cover Salarius' recent achievements, including the acquisition of targeted protein degradation assets for new drug development and updates on the seclidemstat clinical program. Attendees will have access to on-demand content and can schedule one-on-one meetings with the management team. Salarius focuses on developing therapies for sarcomas and pediatric cancers, with its lead candidate seclidemstat currently in clinical trials.

Salarius Pharmaceuticals announces the appointment of Dr. Daniela Santiesteban as Director of their new targeted protein degradation program, focusing on SP-3164. This role follows Salarius' expansion into targeted protein degradation through the acquisition of SP-3164 from DeuteRx. Dr. Santiesteban will oversee SP-3164's clinical trials, expected to file an IND with the FDA in the first half of 2023. SP-3164 aims to treat various cancers, building on the efficacy of previous compounds like avadomide while enhancing safety.

Salarius Pharmaceuticals (Nasdaq: SLRX) has announced a transformative acquisition of a targeted protein degradation portfolio from DeuteRx, significantly enhancing its oncology pipeline. The acquisition includes the lead candidate SP-3164 (formerly DRX-164), which is set to enter clinical trials in 2023. Salarius aims to develop this candidate and additional assets targeting previously undruggable cancer-promoting proteins. The agreement involves an upfront payment of $1.5 million and shares, with potential future payments totaling up to $188 million based on milestones.

Salarius Pharmaceuticals will present at H.C. Wainwright BioConnect and participate in Biotech Showcase and BIO Partnering @ JPM, all virtually alongside the 40th Annual Healthcare Conference 2022. Key dates include Biotech Showcase from January 10-12, H.C. Wainwright BioConnect from January 10-13, and BIO Partnering @ JPM from January 10-14. CEO David Arthur will deliver a presentation on seclidemstat, Salarius' investigational drug for pediatric and other cancers. Salarius has received FDA designations for Ewing sarcoma and aims to expand its clinical trials in cancers with high unmet needs.

Salarius Pharmaceuticals (Nasdaq: SLRX) has achieved a significant milestone by advancing the Ewing sarcoma arm of its Phase 1/2 Sarcoma trial to a second lead-in safety cohort. Patients in this cohort will receive a combination of seclidemstat, topotecan, and cyclophosphamide at a 900 mg BID dosage. The trial aims to assess the safety and efficacy of seclidemstat for relapsed/refractory Ewing sarcoma and FET-rearranged sarcomas. Currently, 13 clinical trial sites are actively enrolling patients, with anticipated data readouts in 2022.

Salarius Pharmaceuticals (Nasdaq: SLRX) announced that CEO David Arthur will present at the Life Science Investor Forum on December 16, 2021. The presentation will cover the company's recent achievements and future milestones related to seclidemstat, a drug in clinical trials for Ewing sarcoma and hematologic cancers. The Phase 1/2 trials are assessing seclidemstat with chemotherapy agents and azacytidine. Investors can register for the event, which will be streamed live, and a recording will be available afterward on the company's website.